Drug major Sun Pharma on Monday said it has received one observation from the US health regulator for its Baska manufacturing facility in Gujarat.
In a regulatory filing, the Mumbai-based company said the US Food and Drug Administration (USFDA) conducted a pre-approval inspection (PAI) of Baska facility from January 28 to February 5, 2019.
“At the conclusion of the inspection, the USFDA issued a Form 483, with one observation for which the company has submitted the response,” it added.
The Baska injectibles plant had recently filed for approvals to sell its products in the US. The manufacturing plant is located near the company’s Halol plant which is already facing regulatory issues from the US health regulator.
Sun Pharma shares closed 1.9 per cent down at Rs 464.10 on the BSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.